## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

<b>STATEMENT</b>	OF CHANGES	IN BENEFICIAL	OWNERSHIP

	OMB APPRO	OVAL					
	OMB Number: 3235-028						
l	Estimated average burden						
l	hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Shah Rajeev M.</u>					2. Issuer Name <b>and</b> Ticker or Trading Symbol  Kala Pharmaceuticals, Inc. [ KALA ]								(Cł	Relationshi neck all ap X Dire	Owner					
(Last) (First) (Middle) C/O RA CAPITAL MANAGEMENT, LLC						3. Date of Earliest Transaction (Month/Day/Year) 10/03/2018									Offic belo	er (give title w)	e	Othe belo	er (specify W)	
20 PARK PLAZA, SUITE 1200  (Street)  BOSTON MA 02116			4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Lin	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting							
(City)	(Sta	ate) (	Zip)		-											Person				
		Tabl	e I - N	lon-Deriv	ative/	Seci	uritie	s Ac	quire	d, Di	sposed o	f, or	3en	eficia	ly Own	ed				
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye					Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3,					Securiti Benefic Owned	curities neficially ned Following		vnership n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				(instr. 4)			
Common Stock 10/03/201					018	18		P		2,424,242	(1)		\$8.25	4,537,478(2)		I		See footnotes <sup>(3)</sup>		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
Derivative Security Price of Derivative Security  Date (Month/Day/Year)  (Month/Day/Year)  Execution Date, if any (Month/Day/Year)  (Month/Day/Year)  Execution Date, if any (Month/Day/Year)		4. Transa Code ( 8)		5. Nu of Deriv Secul Acqu (A) or Dispo of (D) (Instr and 5	ative rities ired osed	6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)  Amour or Numbe of Title Shares		ount	3. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)					

## **Explanation of Responses:**

- 1. Includes (a) 2,000,301 shares of Common Stock that are held by RA Capital Healthcare Fund, L.P.(the "Fund") and (b) 423,941 shares of Common Stock that are held in an account owned by a separately managed account (the "Account").
- $2.\ Following\ the\ reported\ transaction,\ the\ Fund\ held\ 3,727,401\ shares\ and\ the\ Account\ held\ 810,077\ shares.$
- 3. RA Capital Management, LLC (the "Adviser") is the general partner of the Fund and the investment adviser of the Account. Peter Kolchinsky is the sole manager of the Adviser, and Mr. Shah is a managing director of the Adviser. Mr. Shah has no pecuniary interest in the reported securities held in the Account and therefore disclaims beneficial ownership of those securities. Mr. Shah disclaims beneficial ownership of the reported securities held by the Fund except to the extent of his pecuniary interest therein.

<u>/s/ Rajeev Shah</u> <u>10/05/2018</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.